

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

ELI LILLY AND COMPANY,  
Petitioner,

v.

TEVA PHARMACEUTICALS INTERNATIONAL GMBH,  
Patent Owner.

---

CASE IPR2018-01427  
Patent 8,597,649

---

**PATENT OWNER'S MOTION TO EXPUNGE**

***Mail Stop "PATENT BOARD"***  
Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

## **I. Introduction**

Patent Owner Teva Pharmaceuticals International GmbH respectfully submits this Motion to Expunge the confidential version of Exhibit 2257 from the record, per 37 C.F.R. § 42.56. The confidential version of Exhibit 2257 contains information relating to highly-confidential and competitively-sensitive business information that the Board did not rely on it in its Final Written Decision. Further, the public's interests are served by the redacted version of Exhibit 2257. Thus, Petitioner's interests in expunging the confidential version of Exhibit 2257 outweighs the public's interest in maintaining it in the record. Patent Owner certifies that the parties have conferred in good faith regarding this motion, and that Petitioner has indicated that it will not oppose this motion.

## **II. Authorization for the motion**

The Board authorized this motion in the Decision Granting Patent Owner's Combined Unopposed Motions (1) for Entry of Modified Protective Order and (2) to Seal Exhibit 2257, dated October 15, 2019. Paper 46, 6.

## **III. Procedural Background**

On July 1, 2019, Patent Owner filed a Combined Motion for Entry of Modified Protective Order and Motion to Seal Exhibit 2257 (Paper 28; "Combined Motion"). The Board granted Patent Owner's Combined Motion on October 15,

2019. Paper 46. The Board entered its Final Written Decision in this proceeding on February 18, 2020. Paper 78. In the Final Written Decision, the Board expressly stated that it did not rely upon any of the redacted confidential information in reaching its decision:

We granted Patent Owner's Motion to Seal with respect to Exhibit 2257. *See* Paper 48. The record contains both a confidential version and a public, redacted version of Exhibit 2257. Citations herein are to the public version of the document. We do not rely on any of the redacted information for purposes of this Final Written Decision.

Paper 78, 145, n.114.

The confidential version of Exhibit 2257 currently remains under seal and subject to the modified protective order in this proceeding.

#### **IV. Argument**

37 C.F.R. § 42.56 provides: "[a]fter denial of a petition to institute a trial or after final judgment in a trial, a party may file a motion to expunge confidential information from the record." The Board has previously explained that a party moving to expunge has to show that i) "any information sought to be expunged constitutes confidential information" and ii) the movant's interest in expunging the information "outweighs the public's interest in maintaining a complete and

understandable file history." *RPX Corp. v. Virnetx Inc.*, IPR2014-00171, Paper 62, 3 (P.T.A.B. Sept. 9, 2014). The rules identify confidential information as including "a trade secret or other confidential research, development, or commercial information." 37 C.F.R. §§ 42.54(a)(7) and 42.2. And the Board must strike "a balance between the public's interest in maintaining a complete and understandable file history and the parties' interest in protecting truly sensitive information." 37 C.F.R. § 42.54(a); 77 Fed. Reg. 48756, 48760 (Aug. 14, 2012).

In this case, Patent Owner has already demonstrated, and the Board already agreed, that the confidential version of Exhibit 2257 contains highly-confidential, competitively-sensitive business information. Paper 46, 4-5. Broadly, the confidential version of Exhibit 2257 contains information about settlement and license terms between Teva and a third party, Alder Bio, which are of the nature contemplated as protectable under Fed. R. Civ. P. 26(c)(1)(G). Therefore, public disclosure of the confidential version of Exhibit 2257 would cause significant competitive harm not only to Patent Owner, but also to a third party who is not part of this proceeding. There has been no change in the sensitivity or confidentiality of the information contained in the confidential version of Exhibit 2257 since Teva filed its Combined Motion. Thus, Patent Owner has met its burden in showing that

"any information sought to be expunged constitutes confidential information." *RPX Corp. v. Virnetx Inc.*, IPR2014-00171, Paper 62, 3 (P.T.A.B. Sept. 9, 2014).

Patent Owner's interest in expunging the confidential version of Exhibit 2257 "outweighs the public's interest in maintaining a complete and understandable file history." *Id.* None of the redacted portions of the confidential version of Exhibit 2257 are material to this proceeding, as neither party cited to a confidential portion of the confidential version of Exhibit 2257. Further, in the Final Written Decision, the Board expressly stated: "[w]e do not rely on any of the redacted information for purposes of this Final Written Decision." Paper 78, 145, n.114. Moreover, the record contains a public redacted version of Exhibit 2257 that contains all the information upon-which the Board did rely. Accordingly, the public's access to the redacted version of Exhibit 2257 fulfills the public's interest in maintaining a complete and understandable record, and the expungement of the confidential version of Exhibit 2257 from the record will not diminish the public's understanding of the Final Written Decision.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.